CRH Medical reports Q1 2009 results

    (all figures are in US dollars)

    -   Product sales revenue increases 510%
    -   Operating loss narrows significantly
    VANCOUVER, May 26 /PRNewswire-FirstCall/ - CRH Medical Corporation
(CRM:TSX-V) announced today that it recorded revenues of $1,735,890 for the
three months ended March 31, 2009 compared to $1,347,442 for the three
months ended March 31, 2008. The Company reported Clinic operations revenue
of $1,407,197 for the three months ended March 31, 2009 compared to
$1,293,568 for the same period in 2008. Product sales revenue increased
510% to $328,693 for the three months ended March 31, 2009 compared to
$53,874 for the same period in 2008.

    For the three months ended March 31, 2009 the Company reported an
operating loss of $665,060 compared to $970,470 for the same period in
2008, an improvement of 32%. The Company reported a net loss of $705,008
($0.016 per share) for the three months ended March 31, 2009 compared to
$958,738 ($0.021 per share) for the same period in 2008.

    Additionally, the Company announced that as of March 31, 2009 it had
$104,982 in cash and cash equivalents and approximately $1.1 million in
working capital. On April 7, 2009, the Company closed a private placement
financing for net proceeds of approximately $1.8 million.

    Edward Wright, Chief Executive Officer stated, "Our Partnership Program
continues to perform very well during these challenging economic
conditions. The growth of our Partnership Program in combination with our
Center and Corporate cost saving initiatives has reduced our quarterly
operating loss to its lowest level since the first quarter of 2006, which
is in line with our goal of achieving profitability in 2010."

    The Company's December 31, 2008 financial report will be available on
http://www.sedar.com

    About CRH Medical Corporation:

    CRH Medical Corporation specializes in the treatment of hemorrhoids
utilizing its proven treatment protocol and patented proprietary
technology. CRH's single use, disposable, hemorrhoid technology is safe and
highly effective in treating hemorrhoid grades I - IV. CRH Medical employs
two commercialization strategies: First, it operates Centers for Colorectal
Health facilities in the United States specializing in the treatment of
hemorrhoids and fissures, and colon cancer screening. In addition CRH
distributes its hemorrhoid banding technology, treatment protocols,
operational and marketing expertise as a complete, "turn key" package
directly to its partner physicians. The Company's goal is to establish the
CRH hemorrhoid technology as the standard for hemorrhoid treatment.

    The information in this news release contains so-called
"forward-looking" statements. These include statements regarding CRH
Medical's expectations and plans relating to its expansion plans for its
Centers for Colorectal Health, statements about CRH Medical's expectations,
beliefs, intentions or strategies for the future, which may be indicated by
words or phrases such as "anticipate", "expect", "intend", "plan", "will",
"we believe", "CRH Medical believes", "management believes", and similar
language. All forward-looking statements are based on CRH Medical's current
expectations and are subject to risks and uncertainties and to assumptions
made. Important factors that could cause actual results to differ
materially from those expressed or implied by such forward-looking
statements include: (i) changes in the economy may affect the Company's
business; (ii) the Company's ability to successfully recruit and retain
sufficient qualified physicians and other licensed providers; (iii) our
limited available working capital and cash flows and our ability to raise
additional capital as and when needed (iv) the Company's ability to
manufacture its products; (v) the policies of health insurance carriers in
the United States may affect the amount of revenue the Company receives;
(vi) the Company's ability to successfully market its products; (vii)
market acceptance of its technologies and products; (viii) the competitive
environment and impact of technological change; (ix) changes in United
States federal or state laws, rules, and regulations, including but not
limited to those governing the corporate practice of medicine, fee
splitting, Anti-Kickback Statute and Stark Law; * ability to effectively
manage growth and retain senior management personnel; and (xi) product
liability and medical malpractice claims, which may adversely affect our
operations. CRH Medical bases its forward-looking statements on information
currently available to it, and assumes no obligation to update them.



    The TSX Venture Exchange does not accept responsibility for the adequacy
    or accuracy of this release.